Kestra Medical Technologies Reports Strong Q3 FY26 Results with 63% Revenue Growth and Raised FY26 Guidance

summarizeSummary

Kestra Medical Technologies reported strong third-quarter fiscal 2026 financial results, featuring significant revenue growth, expanded gross margins, and an upward revision of its full-year guidance.

check_boxKey Events

• Strong Q3 Revenue Growth

  Reported revenue of $24.6 million for Q3 FY26, marking a 63% increase compared to the prior year period, driven by higher market share and WCD market expansion.

• Expanded Gross Margin

  Gross margin expanded significantly to 52.6% in Q3 FY26, up from 43.4% in the prior year period, attributed to volume leverage and cost improvement programs.

• Raised FY26 Revenue Guidance

  Increased fiscal year 2026 revenue guidance to $93 million, representing 55% growth over FY25, up from previous guidance of $91 million and initial guidance of $85 million.

• Fortified Balance Sheet

  Ended the quarter with $291 million in cash and cash equivalents, which includes net proceeds from an underwritten public offering of 6.9 million common shares that closed on December 4, 2025.

auto_awesomeAnalysis

Kestra Medical Technologies delivered a robust third quarter, showcasing significant operational improvements and strong market penetration. The substantial 63% year-over-year revenue growth, coupled with a notable expansion in gross margin to over 52%, indicates effective execution and improved profitability. The decision to raise full-year revenue guidance for FY26 further reinforces management's confidence in continued momentum. While the company still reports a net loss, these positive financial and operational metrics are critical for a growth-stage medical device company, demonstrating progress towards category leadership and a fortified balance sheet.